title: Obesity hypertension: the rationale for renin-angiotensin system blockade.
authors.affiliation: Qualigenics Diabetes Centre, HKR International Ltd. norman.chan@qualigenics.com
authors.forename: N N
authors.initials: NN
authors.lastname: Chan
authors.forename: P C Y
authors.initials: PC
authors.lastname: Tong
authors.forename: A P S
authors.initials: AP
authors.lastname: Kong
authors.forename: J C N
authors.initials: JC
authors.lastname: Chan
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications* / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents